Baricitinib - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for baricitinib and what is the scope of patent protection?
Baricitinib
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Baricitinib has fifty-six patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for baricitinib
International Patents: | 56 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 101 |
Patent Applications: | 2,603 |
What excipients (inactive ingredients) are in baricitinib? | baricitinib excipients list |
DailyMed Link: | baricitinib at DailyMed |
Recent Clinical Trials for baricitinib
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Phase 4 |
McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A |
Marie Hudson, MD | N/A |
Pharmacology for baricitinib
Drug Class | Janus Kinase Inhibitor |
Mechanism of Action | Janus Kinase Inhibitors |
US Patents and Regulatory Information for baricitinib
International Patents for baricitinib
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Colombia | 6290658 | DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JACK | See Plans and Pricing |
Dominican Republic | P2010000270 | DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK | See Plans and Pricing |
New Zealand | 587928 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | See Plans and Pricing |
South Korea | 20100121657 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | See Plans and Pricing |
Canada | 2718271 | DERIVES D'AZETIDINE ET DE CYCLOBUTANE EN TANT QU'INHIBITEURS DE JANUS KINASE (JAK) (AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS) | See Plans and Pricing |
Norway | 2017033 | See Plans and Pricing | |
Uruguay | 31705 | DERIVADOS DE AZETIDINA Y CICLOBUTANO COMO INHIBIDORES DE JAK | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for baricitinib
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2288610 | 2017/032 | Ireland | See Plans and Pricing | PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213 |
2288610 | 132017000078559 | Italy | See Plans and Pricing | PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215 |
2288610 | 1790035-8 | Sweden | See Plans and Pricing | PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215 |
2288610 | 315 50012-2017 | Slovakia | See Plans and Pricing | PRODUCT NAME: BARICITINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
2288610 | 2017C/025 | Belgium | See Plans and Pricing | PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
2288610 | 33/2017 | Austria | See Plans and Pricing | PRODUCT NAME: BARICITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/16/1170 (MITTEILUNG) 20170215 |
2288610 | LUC00027 | Luxembourg | See Plans and Pricing | PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.